Ishara Investments LP Makes New $2.34 Million Investment in BioCryst Pharmaceuticals, Inc. $BCRX

Ishara Investments LP bought a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 300,000 shares of the biotechnology company’s stock, valued at approximately $2,340,000. BioCryst Pharmaceuticals comprises approximately 2.7% of Ishara Investments LP’s portfolio, making the stock its 11th largest position. Ishara Investments LP owned about 0.14% of BioCryst Pharmaceuticals at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in BCRX. Larson Financial Group LLC raised its holdings in shares of BioCryst Pharmaceuticals by 1,188.0% during the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 3,267 shares during the last quarter. Focus Partners Wealth bought a new stake in shares of BioCryst Pharmaceuticals during the third quarter valued at approximately $77,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of BioCryst Pharmaceuticals by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 2,115 shares during the last quarter. Vestmark Advisory Solutions Inc. bought a new stake in shares of BioCryst Pharmaceuticals during the third quarter valued at approximately $81,000. Finally, Elevation Point Wealth Partners LLC bought a new stake in shares of BioCryst Pharmaceuticals during the third quarter valued at approximately $81,000. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

NASDAQ BCRX opened at $8.95 on Thursday. BioCryst Pharmaceuticals, Inc. has a 12 month low of $6.00 and a 12 month high of $10.32. The firm has a market capitalization of $2.27 billion, a PE ratio of -5.03 and a beta of 0.57. The company’s 50 day simple moving average is $8.92 and its 200 day simple moving average is $8.16.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The company had revenue of $156.41 million for the quarter, compared to analyst estimates of $151.12 million. During the same quarter in the prior year, the business earned $0.20 EPS. BioCryst Pharmaceuticals’s revenue was up 7.5% compared to the same quarter last year. Sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.66 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Needham & Company LLC cut their price target on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Citizens Jmp lifted their price target on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a report on Thursday, May 7th. Evercore assumed coverage on BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They set an “outperform” rating and a $17.00 price target on the stock. Wedbush cut their price target on BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Finally, Wall Street Zen cut BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.70.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.